Ask AI

Looking Ahead With CELMoDs in Lymphoma: Translating Emerging Evidence Into Community Practice

Clinical Thought
Clinical Thought Start Activity
This activity is available for 0.25 CME/CE credit(s).

Released: October 15, 2026

Expiration: April 14, 2027

See Activity Collection

This expert commentary examines emerging evidence for CELMoDs, particularly golcadomide, in lymphoma and considers how these investigational agents may be integrated into community oncology practice. It also reviews efficacy and safety data across lymphoma settings, including combinations with rituximab, chemoimmunotherapy, and bispecific antibodies, while considering practical issues such as adverse event management, differentiation from lenalidomide, treatment accessibility, and academic–community collaboration. Finally, the experts highlight implementation strategies that may help healthcare professionals prepare for CELMoDs while emphasizing the need for ongoing randomized trial data to define their role in routine care.

CELMoDs in Lymphoma Community Practice

Pre Assessment

Assess your current knowledge and clinical approach before beginning your ClinicalThought.
1.

How many people with lymphoma do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

You are educating your team about golcadomide in preparation for managing patients who may be treated with this agent. Which of the following would you explain to them is the most common grade ≥3 adverse event associated with golcadomide?

4.

How often do you discuss clinical trials of novel therapies like CELMoDs with your patients with non-Hodgkin lymphoma?